PDCD1 and head and neck squamous cell carcinoma: The NCT04947241 trial evaluated the safety and effectiveness of the PD‐1 inhibitor toripalimab in combination with gemcitabine and cisplatin as neoadjuvant treatment for resectable LA‐HNSCC [78].